Author

S. R. Stockwell

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Biochemistry· 1 Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Assay:proteomics· 1

Frequent Co-Authors

A. Alcaide· 1 shared A. Asteian· 1 shared A. De Haven Brandon· 1 shared A. Hayes· 1 shared A. Higueruelo· 1 shared A. R. Venkitaraman· 1 shared B. Al-Lazikani· 1 shared B. Blaszczyk· 1 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 24 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBiochemistry

A. Alcaide

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

BiochemistrybioRxivPreprintMar 22, 2023

Selective inhibitors of the Aurora A-TPX2 protein-protein interaction exhibit in vivo efficacy as targeted anti-mitotic agents

S. R. Stockwell, D. E. Scott, G. Fischer…·M. Hyvönen

The paper develops selective Aurora A-TPX2 inhibitors that show in vivo efficacy and synergy with paclitaxel in pancreatic cancer.

DOI 10.1101/2023.03.22.533679

humanproteomics

𝕏 PostBluesky

Cancer BiologybioRxivApr 8, 2019

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

C. Zhang, S. R. Stockwell, M. Elbanna…·S. Mittnacht

This study shows that MET/FAK signaling can activate CDK2 independently of CDK4/6, leading to cell division, and suggests targeting MET/FAK could enhance CDK4/6 inhibitor therapies.

DOI 10.1038/s41388-019-0850-2

humanexperimental assay

𝕏 PostBluesky